Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2017-06-01
Serie:	Blood Advances
Länkar:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!